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Aim: Hyperinsulinemia and insulin resistance are commonly seen in patients with hirsutism and polycystic ovary syndrome (PCOS),
and are associated with cardiovascular disease risk. However, it is not yet known whether insulin-like growth factor I (IGF-I) and
alanine transaminase (ALT) produced by the liver play roles in hyperinsulinemia and subclinical atherosclerotic process in patients with
PCOS and idiopathic hirsutism (IH).
Materials and methods: This was a prospective case-controlled study. The study population consisted of 25 reproductive-age PCOS
women, 33 women with IH, and 25 control subjects.
Results: Mean IGF-I levels and median ALT levels were higher in patients with IH and PCOS than controls, but these differences were
not statistically significant. The participants who had a homeostasis model assessment insulin resistance index (HOMA-IR) greater
than 2.7 had significantly higher IGF-1 and ALT levels. ALT levels were positively correlated with body mass index, FG, insulin and
HOMA-IR.
Conclusion: The study illustrated that IGF-1 and ALT levels were significantly higher in patients with increased insulin resistance.
Due to short disease duration in younger participants, we did not observe any correlation between IGF-1 and hyperinsulinemia. These
findings suggest that increased hepatic production of IGF-I and ALT might be an early indicator of insulin resistance in hirsutism.
Key words: Cardiovascular disease risk, carotid intima media thickness, insulin-like growth factor 1, insulin resistance, polycystic ovary
syndrome

1. Introduction
Polycystic ovary syndrome (PCOS) consists of
hyperandrogenism, menstrual irregularity, anovulation,
infertility, and obesity (1), and is frequently seen in
reproductive-age women (2). Cardiovascular disease
(CVD) risk (3) and early atherosclerosis have been found
to be associated with PCOS (4). Hyperinsulinemia and
insulin resistance are commonly seen in PCOS patients (5)
and are associated with low-grade chronic inflammation
(6) and CVD (7,8).
Chronic elevation of insulin is associated with higher
circulating insulin-like growth factor 1 (IGF-1) levels (9).
Insulin and IGF-1 show their effect via protein receptors
with intrinsic tyrosine kinase activity; they also activate
mitogenic pathways (10).
The relationships between IGF-1, insulin sensitivity,
and CVD risk have not yet been studied in patients with
PCOS and idiopathic hirsutism (IH). Therefore, the aim of
* Correspondence: drevrimcakir@gmail.com

the present study was to evaluate IGF-1 levels in patients
with PCOS and IH, and to assess its association with
cardiometabolic factors including carotid intima media
thickness (CIMT) and insulin resistance.
2. Materials and methods
2.1. Selection of participants
We studied 33 patients with IH, 25 patients with PCOS,
and 25 healthy controls consisting of healthy women who
had regular ovulatory cycles and normal androgen levels.
All 3 groups were matched for age and body mass index
(BMI). The protocol was approved by the local ethics
committee. All patients gave written consent. All patients
were female and nonsmokers. This was a prospective casecontrolled study conducted in a training and research
hospital between September 2011 and March 2012.
The revised diagnostic criteria of PCOS are given as
below (11):
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1. Oligo and/or anovulation.
2. Clinical and/or biochemical signs of
hyperandrogenism.
3. Polycystic ovarian appearance on ultrasound.
Patients with at least 2 of these criteria are defined as
having PCOS.
Those participants who had a smoking history,
diabetes mellitus, hyperprolactinemia, congenital
adrenal hyperplasia, androgen-secreting tumors, thyroid
disorders, Cushing’s syndrome (as determined by a 1
mg dexamethasone suppression test), infectious disease,
hypertension, or hepatic or renal dysfunction were not
included in the study. Patients were excluded if they
had used oral contraceptive agents, antilipidemic drugs,
antihypertensive medications, or insulin-sensitizing drugs
within the 3 months prior to enrollment.
The control group (n = 25) consisted of healthy patients
who had a hirsutism score of <8 and regular menses
without ultrasound appearance of polycystic ovaries.
A Ferriman–Gallwey (FG) score was used to obtain the
degree of hirsutism (12). The BMI, WHR, and hirsutism
scores were evaluated by a single investigator for all of the
subjects.
2.2. Measurement of carotid intima media thickness
Carotid intima media thickness (CIMT) was evaluated
by a high-resolution ultrasound machine (Sonoline G 40,
Siemens) with 7.5-MHz mechanical sector transducer and
a single investigator in our outpatient clinic. The intima
media thickness was measured as the distance between the
blood-intima and media-adventitia on B-mode imaging.
2.3. Biochemical evaluation
Venous blood was sampled from each patient after a 12-h
overnight fast in the follicular phase of a spontaneous
or progesterone-induced menstrual cycle for the
determination of hormone, liver enzyme, lipid profile,
high-sensitive C-reactive protein (hs-CRP), insulin, and
glucose levels.
The glucose oxidase/peroxidase method (Gordion
Diagnostic, Ankara, Turkey) was used to obtain
plasma glucose levels. The serum levels of folliclestimulating hormone (FSH) (normal range: 3–10.9
mIU/mL), luteinizing hormone (LH) (normal range:
2.1–12.8 mIU/mL), prolactin (normal range: 3.1–29.8
ng/mL), estradiol (normal range: 18.9–246.7 pg/mL),
dehydroepiandrosterone sulfate (DHEAS) (normal
range: 35–430 µq/dL), total testosterone (T) (normal
range: 14.2–73.1 ng/dL), insulin (normal range: 3–25
mU/L), and thyroid stimulating hormone (TSH) (normal
range: 0.5– 4.78 mIU/L) were measured with specific
electrochemiluminescence immunoassays (Elecsys 2010
Cobas, Roche Diagnostics, Mannheim, Germany). The
levels of alanine transaminase (ALT), total cholesterol, high
density lipoprotein cholesterol (HDL-C), and triglyceride
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(TG) were determined with enzymatic colorimetric assays
by spectrophotometry (BioSystems S.A., Barcelona,
Spain). The Friedewald formula was used to calculate the
low density lipoprotein cholesterol (LDL-C).
IGF-1
was
evaluated
by
enzyme-labeled
chemiluminescent immunometric assay (Immulite 2000
XP). Serum hs-CRP (normal range: 0–3 mg/L) was
measured by high-sensitive CRP immunonephelometry
(BN, Dade-Behring; Marburg, Germany).
The homeostasis model assessment insulin resistance
index (HOMA-IR) (13), including the formula [fasting
plasma glucose (mmol/L) × fasting serum insulin (mU/
mL) / 22.5] was used to calculate insulin resistance. The
cut-off value was taken as 2.7 for HOMA-IR (14).
2.4. Statistical analyses
Collected data were entered into SPSS version 17.
Continuous data were shown as means ± SD. Chi-squared
tests were used to compare differences in rates. Normally
distributed variables were compared using the one-way
ANOVA. Data that were not normally distributed, as
determined using the Kolmogorov–Smirnov test, were
compared by K independent sample analyses. The data
are expressed as means ± SD. The degree of association
between variables was calculated using the Pearson
correlation coefficient. Multiple linear regression using
the enter method was used to determine the independent
predictors. Univariate analyses were used to adjust the
IGF-1 with respect to age and BMI.
A P value lower than 0.05 was regarded as statistically
significant, and all computed P values were 2-tailed.
3. Results
Clinical and endocrinological parameters were screened in
the patients with PCOS and IH and in the healthy control
subjects (Table 1). We studied 33 patients with IH (mean
age 23.24 ± 5.65 years, range 18–34 years; BMI, 24.86 ±
6.06 kg/m²), 25 patients with PCOS (mean age 22.51 ±
4.07 years, range 18–31 years; BMI, 24.58 ± 4.62 kg/m²),
and 25 age- and BMI-matched healthy controls (mean age
22.36 ± 4.44 years, range 18–32 years; BMI, 22.30 ± 3.66
kg/m²).
3.1. Comparing parameters between groups and the linear
regression analyses
Mean age, BMI, and waist-to-hip ratios were similar between
the groups (P > 0.05). The mean fasting insulin, T, DHEAS,
and CIMT levels were significantly higher and the estradiol
levels were significantly lower in the patients with IH and
PCOS (P < 0.05) (Tables 1 and 2).
The mean IGF-1 levels and median ALT levels were
higher in the patients with IH and PCOS compared with the
controls, but these differences were not statistically significant
(P = 0.120, P = 0.266, respectively) (Table 1). The mean IGF-1
levels are shown as a bar graph in Figure 1. After adjusting

Table 1. The clinical and biochemical data in women with idiopathic hirsutism (IH) and polycystic ovary syndrome (PCOS),
and healthy controls.
PCOS

IH

Control

(n = 25)

(n = 33)

(n = 25)

P

Age, years

22.51 ± 4.07

23.24 ± 5.65

22.36 ± 4.44

0.943

BMI, kg/m2

24.58 ± 4.62

24.86 ± 6.06

22.30 ± 3.66

0.164

Waist-hip ratio

0.84 ± 0.05

0.82 ± 0.06

0.81 ± 0.07

0.138

Ferriman–Gallwey score

9.81 ± 4.98

11.28 ± 3.61

0.20 ± 0.70

< 0.001

Fasting glucose, mg/dL

83.45 ± 8.10

87.60 ± 10.04

88.84 ± 10.05

0.108

Fasting insulin, µIU/mL

15.90 ± 9.71

15.09 ± 7.61

10.63 ± 6.07

0.036

HOMA-IR

3.24 ± 1.90

3.26 ± 1.74

2.36 ± 1.42

0.116

Total cholesterol, mg/dL

165.48 ± 21.89

167.47 ± 44.24

159.32 ± 27.86

0.637

Triglyceride, mg/dL

97.36 ± 66.12

111.86 ± 59.52

87.52 ± 52.45

0.226

HDL-C, mg/dL

52.96 ± 13.05

47.95 ± 9.40

52.52 ± 12.49

0.364

LDL-C, mg/dL

92.84 ± 20.83

96.82 ± 37.30

88.92 ± 23.13

0.603

AST, IU/L

21.15 ± 6.96

19.27 ± 6.10

19.50 ± 2.12

0.837

ALT, IU/L

18.44 ± 13.55

17.17 ± 7.05

14.14 ± 4.56

0.266

IGF1, ng/mL

258.96 ± 112.46

275.84 ± 92.49

220.20 ± 77.34

0.120

hsCRP, mg/L

1.60 ± 1.28

1.65 ± 1.52

0.87 ± 1.10

0.020

Carotid intima media thickness, mm

4.32 ± 0.64

4.47 ± 0.61

3.83 ± 0.49

0.002

HOMA-IR: homeostasis model assessment insulin resistance index; HDL-C: high density lipoprotein cholesterol; LDL-C: Low
density lipoprotein cholesterol; hs-CRP: high-sensitive C- reactive protein.
Table 2. The hormonal value and thyroid volume levels in women with polycystic ovary syndrome (PCOS) and
idiopathic hirsutism (IH), and healthy controls.
PCOS

IH

Control

(n = 25)

(n = 33)

(n = 25)

P

TSH, µIU/mL

1.93 ± 0.91

1.85 ± 0.63

1.89 ± 0.98

0.944

FSH, m IU/mL

5.19 ± 1.86

6.04 ± 1.88

5.94 ± 2.33

0.229

LH, m IU/mL

5.73 ± 2.71

5.65 ± 2.81

4.80 ± 2.27

0.383

Estradiol, pg/mL

57.97 ± 29.30

50.80 ± 19.34

86.54 ± 54.55

0.007

Total testosterone, ng/dL

60.06 ± 23.31

53.04 ± 20.82

42.50 ± 13.65

0.008

PRL, ng/mL

12.76 ± 8.96

12.42 ± 5.98

9.99 ± 5.19

0.384

DHEAS, µq/dL

249.69 ± 130.07

264.65 ± 115.62

172.64 ± 80.43

0.011

fT4: free thyroxine; TSH: thyroid stimulating hormone; FSH: follicule stimulating hormone; LH: luteinizing
hormone; PRL: prolactin; DHEAS: dehydroepiandrosterone sulfate.

for age and BMI, the IGF-1 levels were significantly higher in
patients with IH and PCOS (P < 0.001) (Figure 2). In linear
regression analyses, FG was found to be an independent risk
factor for adjusted IGF-1 (P = 0.002).
3.2. The correlations between parameters
IGF-1 levels were found to be negatively correlated with
age (r: –0.471, P < 0.001) and estradiol (r: –0.240, P =

0.03), whereas they were weakly positively correlated with
FG score (r: 0.232, P = 0.03). ALT levels were found to
be positively correlated with BMI (r: 0.466, P < 0.0001),
HOMA-IR (r: 0.394, P < 0.05), and insulin (r: 0.469, P <
0.001), and weakly correlated with FG score (r: 0.248, p
<0.05), total testosterone levels (r: 0.280, P < 0.05), and
CIMT (r: 0.272, P = 0.037). CIMT measurements were
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Figure 1. Comparison of IGF-1 levels between the groups.

found to be positively correlated with BMI (r: 0.459, P <
0.0001), TG (r: 0.544, P < 0.0001), insulin (r: 0.405, P <
0.0001), hsCRP (r: 0.464, P < 0.0001), FG score (r: 0.329,
P = 0.005), HOMA-IR (r: 0.385, P = 0.001), and ALT (r:
0.272, P = 0.037).
3.3. Comparison of IGF-1 and ALT levels in groups
classified according to HOMA-IR and FG score
The participants were divided into 2 groups according
to HOMA-IR levels. The cut-off point was 2.7 (14). The
participants who had a HOMA-IR greater than 2.7 are
as follows: 15 (45.5%) patients in the PCOS group, 16
(64%) in the IH group, and 8 subjects (32%) in the control
group (P = 0.075). Although the number of patients with
HOMA-IR greater than 2.7 was higher in the PCOS and
IH groups compared with the control, the difference was
not statistically significant.
Those participants who had a HOMA-IR greater
than 2.7 had significantly higher IGF-1 and ALT levels.
Additionally, ALT and IGF-1 levels were higher in the
groups with a higher FG score (FG ≥ 8) (Table 3).
4. Discussion
The results of the present study demonstrate that the
mean IGF-I, ALT, hsCRP, and CIMT levels were higher in
patients with IH and PCOS. Furthermore, IGF-1 showed
an independent association with FG scores. FG scores also
showed a significant correlation with ALT, which reflects
hepatic insulin resistance, according to the study by

PCOS

IH

Figure 2. Comparison of adjusted IGF-1 levels between the
groups.

Bonnet et al. (15). Additionally, IGF-1 and ALT levels were
significantly higher in patients with a HOMA-IR greater
than 2.7. However, there was no relationship between IGF1, HOMA-IR, and CIMT. This is thought to be due to the
younger age of participants.
In the study by Akanji et al., 3099 subjects were
evaluated and it was demonstrated that lower IGF-1
levels were related with increasing numbers of MetS
abnormalities (16). Moreover, in a recent review, authors
have suggested that IGF-1 levels decrease consistently in
subjects with metabolic syndrome and its components,
and in those with ischemic CVD (17).
Although several studies showed that lower IGF-1
levels were associated with increased metabolic syndrome
risk, in the present study we observed higher IGF-1 levels
in insulin-resistant patients. This might be due to the
population of the study, which included PCOS and IH
patients. In relation to this, in a previous study, follicular
fluid concentration of IGF-1 levels were found to be
higher in patients with PCOS, which is consistent with
the present study (18).
Insulin resistance and compensatory hyperinsulinemia
are commonly seen in PCOS. Insulin stimulates hepatic
IGF-1 production and suppresses insulin-like growth
factor binding protein (IGF-BP) production and increases
IGF-1 levels (19–21). Additionally, hyperinsulinemia
stimulates theca-cell receptors via IGF-1 and causes

Table 3. Comparison of the IGF-1 and ALT levels in the HOMA-IR and FG groups.
Groups Variables

HOMA-IR <2.7

HOMA-IR ≥2.7

P

FG score <8

FG score ≥8

P

IGF-1 Mean ± standard deviation

231.94 ± 89.38

280.61 ± 101.72

0.035

220.78 ± 87.89

272.19 ± 100.32

0.020

ALT Mean ± standard deviation

14.84 ± 6.29

16.88 ± 5.39

0.031

14.51 ± 4.68

18.30 ± 12.17

0.160

784

ovarian hyperandrogenemia (22). Furthermore, in a
recent study the IGF-1 receptor was found to play a critical
negative regulator role in insulin sensitivity (23). Likewise,
in the present study, IGF-1 levels were found to be higher
in patients with insulin resistance.
Additionally, women with PCOS have biological or
clinical hyperandrogenemia and it has been shown that
maternal prenatal androgenization causes upregulation
of fetal IGF-1 mRNA expression in adult sheep. Although
circulating testosterone concentrations were not altered in
these sheep, liver androgen receptor was upregulated after
maternal androgen exposure; therefore, these livers may
be more responsive to androgens. The human IGF-1 gene
is known to contain androgen-responsive elements in the
promoter region that bind androgen receptor and stimulate
IGF-1 transcription (24).
In the present study, the FG score, which reflects clinical
hyperandrogenemia, was obtained as an independent risk
factor for increased IGF-1 levels.
There are conflicting data about the relationship between
IGF-1 and increased risk of atherosclerosis and ischemic
heart disease (25–29). In the present study we did not find
any correlation between IGF-1 and CIMT, which reflects
the subclinical atherosclerotic process. This is thought to
be due to the younger age of participants and short disease
duration.

IGF-1 has been found to be a potent mitogen
and antiapoptotic factor. Additionally, in several
epidemiologic in vitro studies and metaanalyses, IGF1 has been found to be associated with cancer risk,
particularly of breast cancer (30–34). Hyperinsulinemia
and increased IGF-1 levels modulate cellular
proliferation, differentiation and apoptosis mechanisms,
and tumor development (35–37). Genetic variation and
polymorphisms also contribute to IGF-1–mediated
cancer risk (30).
Therefore, PCOS and IH patients should be followed
for increased malignancy risk and scanned for breast
cancer at an early age.
The study illustrated that the IGF-1 and ALT levels
were significantly higher in patients with a HOMA-IR
score greater than 2.7. Additionally, increased ALT levels
were found to be associated with hyperinsulinemia.
Due to the short disease duration of younger
participants, we did not observe any correlation between
hyperinsulinemia and IGF-1. These findings suggest that
increased hepatic production of IGF-I and ALT might be
an early indicator of insulin resistance in hirsutism. An
increased FG score was discovered to be an independent
risk factor for elevated IGF-1 levels. Further studies
are needed to evaluate the relationship between IGF-1,
insulin resistance, and atherosclerotic CVD.
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